Cel-Sci Press Release

05/22/2018 - 05:13 CEL-SCI CORPORATION TO PRESENT AT THE 8TH ANNUAL LD MICRO INVITATIONAL
05/02/2018 - 08:34 CEL-SCI CORPORATION ANNOUNCES UPCOMING INVESTOR CONFERENCE PRESENTATIONS
04/09/2018 - 05:34 CEL-SCI CORPORATION TO PRESENT AT THE MICROCAP CONFERENCE
02/05/2018 - 15:21 CEL-SCI TO PRESENT AT 2018 BIO CEO & INVESTOR CONFERENCE
01/30/2018 - 16:54 U.S. PATENT OFFICE ALLOWS NEW CEL-SCI PATENT FOR LEAPS VACCINE PLATFORM TECHNOLOGY
01/16/2018 - 12:34 CEL-SCI ANNOUNCES ADJUSTMENT TO WARRANT EXERCISE PRICE
01/08/2018 - 12:06 CEL-SCI AWARDED PATENT FOR LEAPS VACCINE IN TREATMENT OF RHEUMATOID ARTHRITIS
12/29/2017 - 15:05 CEL-SCI REPORTS FISCAL 2017 FINANCIAL RESULTS AND CLINICAL & CORPORATE DEVELOPMENTS
12/18/2017 - 16:18 CEL-SCI ANNOUNCES ROBERT WATSON JOINS ITS BOARD OF DIRECTORS
12/11/2017 - 12:48 CEL-SCI REACHES FULL ENROLLMENT IN PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY
11/13/2017 - 12:13 CEL-SCI ANNOUNCES UPDATE ON ARBITRATION AGAINST FORMER CLINICAL RESEARCH ORGANIZATION
10/10/2017 - 05:54 CEL-SCI GRANTED EUROPEAN PATENT FOR MULTIKINE'S MECHANISM OF ACTION IN MAKING TUMORS 'VISIBLE' TO THE IMMUNE SYSTEM
10/05/2017 - 09:17 CEL-SCI ANNOUNCES UPDATE ON ONGOING ARBITRATION AGAINST FORMER CLINICAL RESEARCH ORGANIZATION
09/19/2017 - 04:54 CEL-SCI ANNOUNCES $1.5 MILLION NIH SBIR GRANT TO SUPPORT DEVELOPMENT OF RHEUMATOID ARTHRITIS VACCINE
08/23/2017 - 09:03 CEL-SCI ANNOUNCES $3.5 MILLION REGISTERED DIRECT OFFERING
08/14/2017 - 05:53 U.S. FDA REMOVES CLINICAL HOLD ON CEL-SCI'S PHASE 3 HEAD & NECK CANCER TRIAL
06/12/2017 - 13:22 CEL-SCI ANNOUNCES REVERSE STOCK SPLIT
06/08/2017 - 08:33 CEL-SCI ANNOUNCES NEW DATA FOR ITS RHEUMATOID ARTHRITIS VACCINE CANDIDATE PUBLISHED IN PEER REVIEWED JOURNAL
06/05/2017 - 06:20 CEL-SCI SUBMITS FDA RESPONSE FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
05/16/2017 - 11:44 CEL-SCI SCIENTIST PRESENTS AT AAI - IMMUNOLOGY 2017 MEETING
05/01/2017 - 10:20 CEL-SCI ANNOUNCES $1.51 MILLION REGISTERED DIRECT OFFERING
04/28/2017 - 09:11 CEL-SCI RECEIVES INTENT TO GRANT NOTICE FOR NEW MULTIKINE PATENT FROM THE EUROPEAN PATENT OFFICE
04/12/2017 - 05:18 CEL-SCI SCIENTIST PRESENTS AT THE WORLD VACCINE CONGRESS
03/09/2017 - 08:04 CEL-SCI ANNOUNCES $1.5 MILLION REGISTERED DIRECT OFFERING
03/06/2017 - 12:28 CEL-SCI GIVES UPDATE ON PARTIAL CLINICAL HOLD ON PHASE 3 HEAD AND NECK CANCER STUDY WITH MULTIKINE
02/27/2017 - 11:18 CEL-SCI ANNOUNCES THAT THE NYSE MKT APPROVES PLAN
02/21/2017 - 12:57 CEL-SCI SCIENTIST PRESENTS NEW FINDINGS FOR RHEUMATOID ARTHRITIS TREATMENT VACCINE AT CONFERENCE
02/17/2017 - 10:47 CEL-SCI ANNOUNCES $1.0 MILLION REGISTERED DIRECT OFFERING
12/20/2016 - 08:48 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING AND RECEIVES AUDIT OPINION WITH GOING CONCERN EXPLANATION
12/14/2016 - 18:02 CEL-SCI REPORTS FISCAL 2016 FINANCIAL RESULTS AND CLINICAL & CORPORATE DEVELOPMENTS
11/21/2016 - 18:41 CEL-SCI SUBMITS RESPONSE TO FDA IN CONNECTION WITH PARTIAL CLINICAL HOLD ON PHASE 3 CLINICAL TRIAL
11/14/2016 - 07:56 CEL-SCI REPORTS PRECLINICAL DATA SHOWING LEAPS VACCINE IS SUCCESSFUL IN TREATING RHEUMATOID ARTHRITIS
10/21/2016 - 06:48 CEL-SCI PROVIDES UPDATE ON PARTIAL CLINICAL HOLD ON PHASE 3 CLINICAL TRIAL
09/06/2016 - 14:00 CEL-SCI ANNOUNCES RESIGNATION OF ITS FOUNDER FOR HEALTH REASONS
09/02/2016 - 14:35 CEL-SCI REPORTS MONTHLY PATIENT ENROLLMENT IN AUGUST FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
08/01/2016 - 05:12 CEL-SCI REPORTS MONTHLY PATIENT ENROLLMENT IN JULY FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
07/11/2016 - 10:16 CEL-SCI GRANTED EUROPEAN PATENT FOR MULTIKINE CANCER IMMUNOTHERAPY IN COMBINATION WITH RADIATION AND/OR CHEMOTHERAPY
07/05/2016 - 08:47 CEL-SCI REPORTS MONTHLY PATIENT ENROLLMENT IN JUNE FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
06/07/2016 - 11:50 CEL-SCI TO PRESENT AT LD MICRO INVITATIONAL
06/01/2016 - 18:25 CEL-SCI REPORTS MONTHLY PATIENT ENROLLMENT IN MAY FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
05/31/2016 - 15:44 CEL-SCI TO PRESENT AT THE FIFTH ANNUAL MARCUM MICROCAP CONFERENCE
05/24/2016 - 10:40 CEL-SCI ANNOUNCES THE CLOSING OF ITS $5 MILLION REGISTERED DIRECT OFFERING
05/18/2016 - 10:33 CEL-SCI ANNOUNCES $5 MILLION REGISTERED DIRECT OFFERING
01/14/2016 - 08:58 CEL-SCI CORPORATION TO PRESENT AT THE NOBLE FINANCIAL CAPITAL MARKETS' 12TH ANNUAL INVESTOR CONFERENCE
01/05/2016 - 14:45 CEL-SCI REPORTS RECORD YEAR FOR PATIENT ENROLLMENT WITH 75% INCREASE IN ITS GLOBAL PHASE 3 HEAD AND NECK CANCER TRIAL
12/01/2015 - 22:33 CEL-SCI REPORTS MONTHLY PATIENT ENROLLMENT IN NOVEMBER FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
11/30/2015 - 20:18 CEL-SCI CORPORATION TO PRESENT AT THE LD MICRO MAIN EVENT
11/17/2015 - 15:06 CEL-SCI IS GRANTED A NEW EUROPEAN PATENT ON ITS PHASE 3 INVESTIGATIONAL CANCER IMMUNOTHERAPY MULTIKINE
11/04/2015 - 10:16 CEL-SCI's RHEUMATOID ARTHRITIS VACCINE SELECTED FOR COMMERCIALIZATION & PROGRAM NICHE ANALYSIS PLAN BY U.S. NATIONAL INSTITUTES OF HEALTH
11/02/2015 - 12:05 CEL-SCI REPORTS RECORD MONTHLY PATIENT ENROLLMENT IN OCTOBER FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
10/28/2015 - 14:05 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING FOR GROSS PROCEEDS OF $11.5 MILLION
10/23/2015 - 08:20 CEL-SCI PRICES PUBLIC OFFERING FOR UP TO $12 MILLION
10/14/2015 - 10:29 CEL-SCI TO RECEIVE UP TO $5,000,000 IN LITIGATION FUNDING TO SUPPORT ITS ARBITRATION SUIT AGAINST FORMER CRO
10/05/2015 - 20:49 ERGOMED INCREASES ITS CO-DEVELOPMENT CONTRIBUTION UP TO $12,000,000 IN CEL-SCI'S PHASE 3 HEAD AND NECK CANCER TRIAL
09/01/2015 - 02:16 CEL-SCI REPORTS AUGUST PATIENT ENROLLMENT FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
08/03/2015 - 07:56 CEL-SCI REPORTS RECORD MONTHLY PATIENT ENROLLMENT IN JULY FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL
07/01/2015 - 10:13 CEL-SCI REPORTS JUNE PATIENT ENROLLMENT IN ITS PHASE 3 HEAD AND NECK CANCER TRIAL
06/16/2015 - 08:47 CEL-SCI TO PRESENT AT THE 2015 BIO INTERNATIONAL CONVENTION
06/08/2015 - 10:50 CEL-SCI IS CLEARED TO START PATIENT ENROLLMENT FOR ITS PHASE 3 CANCER IMMUNOTHERAPY TRIAL IN THAILAND
06/01/2015 - 07:55 CEL-SCI REPORTS MAY PATIENT ENROLLMENT IN ITS PHASE 3 HEAD AND NECK CANCER TRIAL
05/29/2015 - 14:57 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING FOR GROSS PROCEEDS OF $16 MILLION
05/27/2015 - 11:12 CEL-SCI TO PRESENT AT THE 2015 MARCUM MICROCAP CONFERENCE
05/22/2015 - 07:56 CEL-SCI PRICES UP TO $16 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS
05/21/2015 - 16:22 CEL-SCI ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS
05/11/2015 - 10:48 CEL-SCI RECEIVES AUTHORIZATION TO CONDUCT ITS PHASE 3 MULTIKINE TRIAL IN ITALY
05/11/2015 - 07:37 CEL-SCI RECEIVES AUTHORIZATION TO CONDUCT ITS PHASE 3 MULTIKINE TRIAL IN SPAIN
05/06/2015 - 10:42 CEL-SCI ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
04/13/2015 - 16:48 UK's AINTREE UNIVERSITY HOSPITAL JOINS CEL-SCI'S PHASE III HEAD AND NECK CANCER TRIAL
02/27/2015 - 14:30 CEL-SCI COMPLETES KEY MILESTONE WITH CLEARANCE TO CONDUCT PHASE III TRIAL IN 21 COUNTRIES
02/20/2015 - 14:30 CEL-SCI TO PARTICIPATE IN ASCENDIANT'S QUARTERLY MANAGEMENT DISCUSSION SERIES TODAY, FRIDAY FEBRUARY 20 AT 11 AM EASTERN TIME
02/18/2015 - 08:25 CEL-SCI TO PRESENT AT 3rd ANNUAL SACHS CANCER BIO PARTNERING & INVESTMENT FORUM
02/05/2015 - 17:23 CEL-SCI TO PRESENT AT 17TH ANNUAL BIO CEO & INVESTOR CONFERENCE
02/02/2015 - 14:55 CEL-SCI REPORTS RECORD MONTHLY PATIENT ENROLLMENT IN ITS PHASE III HEAD AND NECK CANCER TRIAL
01/26/2015 - 14:55 CEL-SCI RECEIVES REGULATORY CLEARANCE TO EXPAND ITS PHASE III HEAD AND NECK CANCER TRIAL INTO ROMANIA
01/09/2015 - 11:28 CEL-SCI TO PRESENT AT BIOTECH SHOWCASE 2015
01/06/2015 - 08:28 DATE SET FOR ARBITRATION TRIAL BETWEEN CEL-SCI AND CLINICAL RESEARCH ORGANIZATION INVENTIV
01/05/2015 - 02:28 CEL-SCI's 2014 PATIENT ENROLLMENT INCREASES EIGHT-FOLD OVER 2013 IN ITS PHASE III HEAD AND NECK CANCER TRIAL
12/08/2014 - 07:52 CEL-SCI EXPANDS ITS PIVOTAL PHASE III IMMUNOTHERAPY HEAD AND NECK CANCER TRIAL WITH ADDITION OF 7 MORE CLINICAL SITES
11/03/2014 - 11:08 CEL-SCI ENROLLS 22 PATIENTS DURING OCTOBER IN ITS PHASE III IMMUNOTHERAPY HEAD AND NECK CANCER TRIAL
10/24/2014 - 00:55 CEL-SCI CORPORATION ANNOUNCES CLOSING OF PUBLIC OFFERING FOR GROSS PROCEEDS OF $6 MILLION
10/21/2014 - 12:57 CEL-SCI CORPORATION TO RAISE $1 MILLION IN REGISTERED DIRECT OFFERING
10/21/2014 - 12:57 CEL-SCI CORPORATION PRICES $6 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS
10/03/2014 - 15:52 CEL-SCI ENROLLS 16 PATIENTS IN SEPTEMBER IN ITS PHASE III IMMUNOTHERAPY HEAD AND NECK CANCER TRIAL
09/10/2014 - 09:57 UNIVERSITY OF MINNESOTA MASONIC CANCER CENTER JOINS CEL-SCI'S PHASE III HEAD & NECK CANCER TRIAL
09/03/2014 - 10:01 CEL-SCI ENROLLS 20 PATIENTS IN AUGUST IN ITS PHASE III IMMUNOTHERAPY HEAD AND NECK CANCER TRIAL
07/22/2014 - 10:07 CEL-SCI RECEIVES REGULATORY CLEARANCE TO EXPAND PHASE III HEAD AND NECK CANCER TRIAL INTO TURKEY
07/17/2014 - 10:07 CEL-SCI EXPANDS ITS PHASE III HEAD AND NECK CANCER TRIAL INTO SRI LANKA
07/15/2014 - 13:06 CEL-SCI RECEIVES $225,000 NIH RESEARCH GRANT TO DEVELOP RHEUMATOID ARTHRITIS TREATMENT
07/11/2014 - 07:03 CEL-SCI PRESENTS RHEUMATOID ARTHRITIS DATA AT THE 12TH VACCINES RESEARCH & DEVELOPMENT: ALL THINGS CONSIDERED CONFERENCE
07/08/2014 - 07:01 CEL-SCI RECEIVES REGULATORY CLEARANCE TO EXPAND CEL-SCI'S PHASE III HEAD AND NECK CANCER TRIAL INTO AUSTRIA
06/18/2014 - 07:01 CEL-SCI TO PRESENT AT THE 2014 BIO INTERNATIONAL CONVENTION
06/02/2014 - 07:01 CEL-SCI RECEIVES APPROVAL TO EXPAND ITS IMMUNOTHERAPY PHASE III HEAD AND NECK CANCER TRIAL INTO THE UNITED KINGDOM
05/27/2014 - 07:01 UNIVERSITY OF CINCINNATI CANCER INSTITUTE'S COMPREHENSIVE HEAD AND NECK CANCER CENTER JOINS CEL-SCI'S PHASE III TRIAL
04/29/2014 - 08:51 CEL-SCI CORPORATION RECEIVES $3 MILLION FROM WARRANT EXERCISES
04/22/2014 - 08:49 CEL-SCI TO SPONSOR SYMPOSIUM ON MULTIKINE AT EUROPEAN CONGRESS ON HEAD & NECK ONCOLOGY 2014
04/17/2014 - 10:51 CEL-SCI CORPORATION ANNOUNCES CLOSING OF PUBLIC OFFERING FOR GROSS PROCEEDS OF $10 MILLION
04/14/2014 - 07:48 CEL-SCI CORPORATION PRICES $10 MILLION PUBLIC OFFERING OF COMMON STOCK AND SIX MONTH WARRANTS
04/11/2014 - 14:48 CEL-SCI CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND SIX MONTH WARRANTS
04/02/2014 - 10:47 ARIZONA CANCER RESEARCH ALLIANCE & 21ST CENTURY ONCOLOGY TO ENROLL PATIENTS IN CEL-SCI'S GLOBAL PHASE III HEAD AND NECK CANCER TRIAL
04/01/2014 - 10:51 CEL-SCI REPORTS MARCH 2014 IS RECORD MONTH FOR PATIENT ENROLLMENT IN PHASE III HEAD AND NECK CANCER TRIAL
Copy and paste this code to display this page on your website .
Syndicate content